Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial

These data describe clinical and immunological parameters acquired during the execution of the DECENDO study. In this phase I/II clinical trial, seven patients with metastatic endometrial cancer were included. Patients underwent chemotherapy (carboplatin/paclitaxel) and a dendritic cell (DC) therapy based on natural dendritic cells. The primary endpoint was immunological vaccine efficacy. Immunological efficacy was assessed in T-cells obtained from biopsies from delayed-type hypersensitivity (DTH-)challenged skin sites, as well as in T-cells obtained from peripheral blood. Exploratory analyses were performed using flow cytometry of peripheral blood mononuclear cells (PBMCs) as well as using multispectral microscopy of tumor biopsies.

The data in this repository include: survival data, clinical response data, DC product characteristics, functionality of antigen-specific T-cells, response to a positive control antigen, analysis of immune cells in peripheral blood, multiplex immunohistochemistry analysis of tumor tissue.

Data are categorized in folders. Folder names refer to the figure numbers in the associated publication that describe the underlying data.